Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Income from Continuing Operations (2016 - 2025)

China Pharma Holdings' Income from Continuing Operations history spans 16 years, with the latest figure at 1222135.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations changed 0.19% year-over-year to 1222135.0; the TTM value through Dec 2025 reached 3187556.0, up 32.7%, while the annual FY2025 figure was 3187556.0, 32.7% up from the prior year.
  • Income from Continuing Operations reached 1222135.0 in Q4 2025 per CPHI's latest filing, down from 651482.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 475976.0 in Q1 2023 to a low of 1438130.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 918752.8, with a median of 857531.5 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: crashed 6418.56% in 2021, then surged 63.26% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 980719.0 in 2021, then dropped by 28.9% to 1264184.0 in 2022, then increased by 2.53% to 1232213.0 in 2023, then grew by 0.63% to 1224432.0 in 2024, then rose by 0.19% to 1222135.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Income from Continuing Operations are 1222135.0 (Q4 2025), 651482.0 (Q3 2025), and 528367.0 (Q2 2025).